Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Expands By 24.3%

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 570,220 shares, an increase of 24.3% from the February 12th total of 458,764 shares. Currently, 14.9% of the company’s stock are sold short. Based on an average daily trading volume, of 844,062 shares, the short-interest ratio is currently 0.7 days. Based on an average daily trading volume, of 844,062 shares, the short-interest ratio is currently 0.7 days. Currently, 14.9% of the company’s stock are sold short.

Oragenics Stock Performance

Shares of Oragenics stock traded down $0.09 during mid-day trading on Monday, hitting $0.80. 232,617 shares of the stock were exchanged, compared to its average volume of 601,114. Oragenics has a 12 month low of $0.61 and a 12 month high of $9.60. The company has a 50-day simple moving average of $0.82 and a 200 day simple moving average of $1.00. The company has a market capitalization of $3.42 million, a P/E ratio of -0.07 and a beta of 1.09.

Hedge Funds Weigh In On Oragenics

Institutional investors have recently added to or reduced their stakes in the stock. DRW Securities LLC increased its holdings in Oragenics by 82.4% during the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after buying an additional 50,900 shares during the last quarter. Clear Street LLC bought a new position in shares of Oragenics during the 2nd quarter valued at approximately $270,000. Sabby Management LLC bought a new position in shares of Oragenics during the 3rd quarter valued at approximately $77,000. XTX Topco Ltd purchased a new stake in shares of Oragenics during the 4th quarter worth approximately $26,000. Finally, Bank of America Corp DE increased its stake in shares of Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after purchasing an additional 15,338 shares during the last quarter. Institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.